WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Abstract

Conflict of interest: COI declared -see noteCOI notes: M.M. is a former employee at AstraZeneca, academically collaborates with AstraZeneca, GSK and Roche, and receives funding from GSK and Roche. Preprint server: No; Author contributions and disclosures: M.G. designed all experiments, performed PDX experiments and designed figures; Y.G. performed certain PDX experiments, all cell line experiments and designed figures; D.A. performed CLUE cloning; G.K. and M.M. analysed DepMap data; B.V. established PDX models and in vivo chemotherapy protocols; K.S. provided primary AML samples; M.R.T. and K.H.M. performed panel sequencing; E.B. and V.J. analysed the scrb seq data; and I.J. designed the study, guided the experiments and wrote the manuscript, with the help of all authors. Non-author contributions and disclosures: No;Agreement to Share Publication-Related Data and Data Sharing Statement: Transcriptome data generated in this study are publicly available in Gene Expression Omnibus (GEO) at (XXX ID will be provided before publication). Proteome data generated in this study are publicly available in Proteomics Identification Database (PRIDE) at (XXX ID will be provided before publication). Whole Exome Sequencing raw data generated in this study are not publicly available due to information that could compromise patient privacy or consent but are available upon reasonable request from the corresponding author. Clinical trial registration information (if any):